Company Filing History:
Years Active: 2022-2023
Title: Kozo Yoneda: Innovator in Antitumor Antibody Development
Introduction
Kozo Yoneda is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of novel therapeutic antibodies. With a total of 2 patents to his name, Yoneda's work focuses on enhancing antitumor efficacy through innovative approaches.
Latest Patents
Yoneda's latest patents revolve around the Anti-CD147 antibody. The primary objective of this invention is to provide a novel anti-CD147 antibody that exhibits potent antitumor efficacy while ensuring excellent safety. This invention also includes a pharmaceutical product that comprises such an antibody. Furthermore, it outlines a method for treating tumors using the antibody or the pharmaceutical product. The present invention introduces a CD147-specific antibody that activates CD147 and demonstrates high antitumor efficacy. Notably, this anti-CD147 antibody exhibits high antitumor efficacy independent of effector functions. Additionally, the invention provides a pharmaceutical composition that includes this anti-CD147 antibody, along with methods for treating tumors using the antibody and/or pharmaceutical composition.
Career Highlights
Kozo Yoneda is associated with Daiichi Sankyo Company, Limited, where he continues to advance his research and development efforts. His work has been instrumental in pushing the boundaries of cancer treatment through innovative antibody therapies.
Collaborations
Yoneda collaborates with esteemed colleagues, including Keisuke Fukuchi and Kayoko Nanai, to further enhance the impact of his research in the field of biotechnology.
Conclusion
Kozo Yoneda's contributions to the development of the Anti-CD147 antibody exemplify his commitment to advancing cancer treatment. His innovative work continues to pave the way for new therapeutic options in oncology.